In a filing, Avidity Biosciences Inc revealed its Chief Human Resources Officer McCarthy Teresa unloaded Company’s shares for reported $0.47 million on Aug 15 ’25. In the deal valued at $46.56 per share,10,000 shares were sold. As a result of this transaction, McCarthy Teresa now holds 97,130 shares worth roughly $4.28 million.
Then, TERESA MCCARTHY bought 45,000 shares, generating $2,073,150 in total proceeds.
Before that, MacLean Michael F sold 30,914 shares. Avidity Biosciences Inc shares valued at $1,320,844 were divested by the Chief Financial Officer at a price of $42.73 per share. As a result of the transaction, MacLean Michael F now holds 65,806 shares, worth roughly $2.9 million.
A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. Wolfe Research began covering RNA with “an Outperform” recommendation on June 17, 2025. Raymond James started covering the stock on June 11, 2025. It rated RNA as “a Strong buy”.
Price Performance Review of RNA
On Tuesday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -1.03% to $44.02. Over the last five days, the stock has lost -4.78%. Avidity Biosciences Inc shares have fallen nearly -3.23% since the year began. Nevertheless, the stocks have risen 51.38% over the past one year. While a 52-week high of $56.00 was reached on 08/06/25, a 52-week low of $21.51 was recorded on 04/09/25.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 42.88, which if violated will result in even more drops to 41.73. On the upside, there is a resistance level at 44.96. A further resistance level may holdings at 45.89.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-07-31, dropping by -0.51 million shares to a total of 16.21 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 16.72 million shares. There was a decline of -3.15%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 13, 2025 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
